<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36999279</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>03</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1473-2300</ISSN><JournalIssue CitedMedium="Internet"><Volume>51</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Mar</Month></PubDate></JournalIssue><Title>The Journal of international medical research</Title><ISOAbbreviation>J Int Med Res</ISOAbbreviation></Journal><ArticleTitle>A case report of systemic lupus erythematosus combined with central serous chorioretinopathy treated with glucocorticoids.</ArticleTitle><Pagination><StartPage>3000605231163716</StartPage><MedlinePgn>3000605231163716</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">03000605231163716</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1177/03000605231163716</ELocationID><Abstract><AbstractText>Glucocorticoids are generally contraindicated for use in central serous chorioretinopathy (CSC) because their use is considered to be an independent risk factor for CSC. There are rare reports regarding the treatment of systemic lupus erythematosus (SLE) combined with CSC. This current case report describes a rare case of a 24-year-old female patient with severely active SLE combined with CSC, whose vision was significantly restored after she was administered 120&#x2009;mg methylprednisolone intravenously once a day for 3 days. This case report presents the clinical characteristics for the first time in terms of distinguishing between typical CSC and lupus chorioretinopathy. It also provides a review of the relevant literature. In patients with clinically severe active lupus nephritis combined with bilateral lupus chorioretinopathy, timely systemic application of appropriate doses of glucocorticoids is the preferred method to control the primary disease and serious ocular complications.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rao</LastName><ForeName>Qingqing</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Graduate School of Shenzhen University, Shenzhen, Guangdong Province, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Nephrology, Shenzhen Second People's Hospital, First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ku</LastName><ForeName>Ming</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Shenzhen Second People's Hospital, First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wan</LastName><ForeName>Qijun</ForeName><Initials>Q</Initials><Identifier Source="ORCID">0000-0002-1304-1333</Identifier><AffiliationInfo><Affiliation>Department of Nephrology, Shenzhen Second People's Hospital, First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong Province, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Int Med Res</MedlineTA><NlmUniqueID>0346411</NlmUniqueID><ISSNLinking>0300-0605</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance></Chemical><Chemical><RegistryNumber>X4W7ZR7023</RegistryNumber><NameOfSubstance UI="D008775">Methylprednisolone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005938" MajorTopicYN="N">Glucocorticoids</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056833" MajorTopicYN="Y">Central Serous Chorioretinopathy</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008775" MajorTopicYN="N">Methylprednisolone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005123" MajorTopicYN="N">Eye</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Central serous chorioretinopathy</Keyword><Keyword MajorTopicYN="N">case report</Keyword><Keyword MajorTopicYN="N">glucocorticoids</Keyword><Keyword MajorTopicYN="N">lupus chorioretinopathy</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus</Keyword></KeywordList><CoiStatement>The authors declare that there are no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>3</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>31</Day><Hour>3</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36999279</ArticleId><ArticleId IdType="pmc">PMC10068993</ArticleId><ArticleId IdType="doi">10.1177/03000605231163716</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Merrill JT, Buyon JP, Utset T. A 2014 update on the management of patients with systemic lupus erythematosus. Semin Arthritis Rheum 2014; 44: e1&#x2013;e2.</Citation><ArticleIdList><ArticleId IdType="pubmed">25437901</ArticleId></ArticleIdList></Reference><Reference><Citation>Shoughy SS, Tabbara KF. Ocular findings in systemic lupus erythematosus. Saudi J Ophthalmol 2016; 30: 117&#x2013;121.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4908056</ArticleId><ArticleId IdType="pubmed">27330388</ArticleId></ArticleIdList></Reference><Reference><Citation>Conigliaro P, Cesareo M, Chimenti MS, et al.. Take a look at the eyes in Systemic Lupus Erythematosus: A novel point of view. Autoimmun Rev 2019; 18: 247&#x2013;254.</Citation><ArticleIdList><ArticleId IdType="pubmed">30639641</ArticleId></ArticleIdList></Reference><Reference><Citation>Turk MA, Hayworth JL, Nevskaya T, et al.. Ocular Manifestations in Rheumatoid Arthritis, Connective Tissue Disease, and Vasculitis: A Systematic Review and Metaanalysis. J Rheumatol 2021; 48: 25&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">32358156</ArticleId></ArticleIdList></Reference><Reference><Citation>van Rijssen TJ, van Dijk EHC, Yzer S, et al.. Central serous chorioretinopathy: Towards an evidence-based treatment guideline. Prog Retin Eye Res 2019; 73: 100770.</Citation><ArticleIdList><ArticleId IdType="pubmed">31319157</ArticleId></ArticleIdList></Reference><Reference><Citation>Khng CG, Yap EY, Au-Eong KG, et al.. Central serous retinopathy complicating systemic lupus erythematosus: a case series. Clin Exp Ophthalmol 2000; 28: 309&#x2013;313.</Citation><ArticleIdList><ArticleId IdType="pubmed">11021562</ArticleId></ArticleIdList></Reference><Reference><Citation>Gagnier JJ, Kienle G, Altman DG, et al.. The CARE guidelines: consensus-based clinical case reporting guideline development. Headache 2013; 53: 1541&#x2013;1547.</Citation><ArticleIdList><ArticleId IdType="pubmed">24266334</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato H, Ito S, Nagai S, et al.. Atypical severe central serous chorioretinopathy in a patient with systemic lupus erythematosus improved with a rapid reduction in glucocorticoid. Mod Rheumatol 2013; 23: 172&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pubmed">22447556</ArticleId></ArticleIdList></Reference><Reference><Citation>Haimovici R, Koh S, Gagnon DR, et al.. Risk factors for central serous chorioretinopathy: a case&#x2013;control study. Ophthalmology 2004; 111: 244&#x2013;249.</Citation><ArticleIdList><ArticleId IdType="pubmed">15019370</ArticleId></ArticleIdList></Reference><Reference><Citation>Rim TH, Kim HS, Kwak J, et al.. Association of Corticosteroid Use With Incidence of Central Serous Chorioretinopathy in South Korea. JAMA Ophthalmol 2018; 136: 1164&#x2013;1169.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6233821</ArticleId><ArticleId IdType="pubmed">30098167</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasanreisoglu M, Gulpinar Ikiz GD, Kucuk H, et al.. Acute lupus choroidopathy: multimodal imaging and differential diagnosis from central serous chorioretinopathy. Int Ophthalmol 2018; 38: 369&#x2013;374.</Citation><ArticleIdList><ArticleId IdType="pubmed">28050729</ArticleId></ArticleIdList></Reference><Reference><Citation>Dammacco R. Systemic lupus erythematosus and ocular involvement: an overview. Clin Exp Med 2018; 18: 135&#x2013;149.</Citation><ArticleIdList><ArticleId IdType="pubmed">29243035</ArticleId></ArticleIdList></Reference><Reference><Citation>Edouard S, Douat J, Sailler L, et al.. Bilateral choroidopathy in systemic lupus erythematosus. Lupus 2011; 20: 1209&#x2013;1210.</Citation><ArticleIdList><ArticleId IdType="pubmed">21511760</ArticleId></ArticleIdList></Reference><Reference><Citation>Benitez del Castillo J, Castillo A, Fernandez-Cruz A, et al.. Persistent choroidopathy in systemic lupus erythematosus. Doc Ophthalmol 1994; 88: 175&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pubmed">7781485</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>